SECsense Logo

Outlook Therapeutics, Inc. 8-K Report: Key Updates from December 27, 2024

$OTLK
Form 8-K
Filed on: 2024-12-27
Source
Outlook Therapeutics, Inc. 8-K Report: Key Updates from December 27, 2024

Based on the provided section of the financial report, here are the key pieces of information:

  1. Entity Information:
  • Company Name: Outlook Therapeutics, Inc.
  • CIK Number: 0001649989
  • SEC File Number: 001-37759
  • EIN: 38-3982704
  • Address: 111 S. Wood Avenue, Unit #100, Iselin, NJ 08830
  • Phone Number: 609-619-3990
  1. Filing Details:
  • Filing Type: 8-K
  • Filing Date: December 27, 2024
  1. Stock Information:
  • Common Stock Ticker: OTLK
  • Exchange: NASDAQ
  1. Context Information:
  • Reporting Date: December 27, 2024
  • Period Covered: The report covers a single day, indicating a specific event or material change on that date.
  1. Units of Measure:
  • Currency: United States Dollar (USD)
  • Shares: The report includes share-related data, although specific share counts or financial measures are not detailed in the provided section.

Insights:

  • The report is likely related to a significant event or announcement by Outlook Therapeutics, as indicated by the use of an 8-K filing, which is used to report unscheduled material events.
  • The presence of specific identifiers (CIK, SEC file number) and company details suggests that this is a formal regulatory filing that provides transparency to investors and stakeholders.
  • The report could be of particular interest to investors in the biotech sector, given that Outlook Therapeutics operates in that space.

Overall, this section establishes the context for the company's recent activities and provides essential identifiers for further investigation into its financial and operational status.